Sign in
CompletedNo phase

Dexmedetomidine Enhancing the Recovery After Cardiac Surgery

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
75 people enrolled
Started
30 Aug 2024
Ended
31 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidine
  • Fentanyl
  • Lidocain
Record updated
2 April 2025

Who can take part

Age
40 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients of American Society of Anesthesiologists Classification (ASA) grade II-III
  • Patients who were planned to have Coronary Artery Bypass Graft (CABG)
  • Patients were free of exclusion criteria

Who cannot take part

  • Patients with preoperative high risk for getting Post Operative Delirium or sleep disorders,
  • Patients with uncontrolled diabetes mellitus, coagulopathy, or history of uncompensated renal or hepatic diseases
  • Patients with heart failure, left ventricle ejection fraction of <25%,
  • Patients with American Society of Anesthesiologists Classification (ASA) grade>III

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Enhanced Recovery After Surgery (ERAS) aims to facilitate a quicker and smoother recovery period following surgical procedures. The implementation of these protocols may lead to patients returning to their daily activities sooner, experiencing greater satisfaction with their care, and potentially encountering fewer complications, ultimately contributing to shorter hospital stays. However, a common challenge in the postoperative phase is postoperative delirium(POD). This complication can lead to both immediate and long-term cognitive impairments, negatively impact overall health outcomes, and increase the financial burden on the healthcare system. Interestingly, dexmedetomidine, known as DXM, is a medication that selectively targets certain receptors in the brain and offers sedative properties with minimal impact on breathing. This characteristic is noteworthy because it may help regulate sleep patterns and support the preservation of cognitive function during the recovery period.

The 2 groups in the trial

  • Group DExisting treatment, for comparison

    Treatment: Dexmedetomidine and Lidocain

  • Group FExisting treatment, for comparison

    Treatment: Fentanyl

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dexmedetomidine-based Enhanced Recovery After Cardiac Surgery Improves Outcome Regarding Analgesia, Sleep Disorders, and Postoperative Delirium
Record updated
2 April 2025